Anthera Pharmaceuticals's total revenue is $0, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2018
Trailing 12 months ending Mar 2018
The latest total revenue for ANTH is $0 as of March 2018. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Anthera Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Over the past year, ANTH's total revenue moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Anthera Pharmaceuticals's operating scale or balance-sheet position.
Against Healthcare companies, ANTH currently prints $0 for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Anthera Pharmaceuticals's growth, margins, and balance sheet.
A total revenue figure of $0 for ANTH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.
After noting ANTH's total revenue ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.